04 Obesity Treatment Used in studies focusing on obesity management and metabolic health
Although concrete evidence regarding its effect on cardiovascular outcomes is pending, it is worth noting that the same active compound, when given subcutaneously in the SUSTAIN-6 trial, reduced the occurrence of major adverse cardiovascular events (MACE) compared to a placebo [7]
Some people feel appetite suppression remains solid at a lower weekly dose
In that context, the researchers examined the insurance claims of nearly 3,600 pregnancies among women taking GLP-1s, some of whom continued to do so during the first trimester of pregnancy and some of whom stopped
Revised: April 2026 INSTRUCTIONS FOR USE ZEPBOUND [ZEHP-bownd] (tirzepatide) injection, for subcutaneous use Multi-dose vial Each vial contains 4 doses, one dose taken weekly